HYUNDAI BIOSCIENCE CO., LTD.
Clinical-stage biotech developing safer antiviral & anticancer drugs via advanced drug delivery systems.
048410 | KO
Overview
Corporate Details
- ISIN(s):
- KR7048410005
- LEI:
- Country:
- South Korea
- Address:
- 경상북도 김천시 아포읍 아포공단길 106, 김천시
- Sector:
- Mining and quarrying
- Industry:
- Mining of non-ferrous metal ores
Description
HYUNDAI BIOSCIENCE CO., LTD. is a clinical-stage biotechnology company focused on developing and commercializing innovative therapeutics through its advanced drug delivery systems (DDS) and bio-fusion technologies. The company's core mission is to create safer and more effective treatments for critical diseases. Its development pipeline features CP-COV03, a broad-spectrum antiviral drug candidate designed to treat viral infections by enhancing cellular autophagy, and Polytaxel, a next-generation anticancer agent engineered to minimize toxicity and patient discomfort. The company's proprietary technology platform, utilizing organic-inorganic hybrid materials, also underpins its commercialized bio-functional products. Through strategic partnerships with global universities and companies, Hyundai Bioscience aims to contribute significantly to human health and life extension.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-09-16 00:00 |
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
|
Korean | 113.3 KB | ||
| 2025-09-16 00:00 |
Legal Proceedings Report
투자판단관련주요경영사항(임상시험계획변경승인신청) (뎅기 또는 뎅기 유사 질환 환자를 대상으로 CPCOV03의 2/3상 …
|
Korean | 13.7 KB | ||
| 2025-09-08 00:00 |
Regulatory News Service
투자판단관련주요경영사항(임상시험계획변경승인) (전립선암 치료제 CPPCA07의 1상 임상시험계획 변경승인)
|
Korean | 12.7 KB | ||
| 2025-09-02 00:00 |
Regulatory News Service
투자판단관련주요경영사항(임상시험계획변경승인신청) (전립선암 치료제 CPPCA07의 1상 임상시험계획 변경승인 신청)
|
Korean | 11.6 KB | ||
| 2025-08-25 00:00 |
Annual Report
[기재정정]사업보고서 (2024.12)
|
Korean | 1.7 MB | ||
| 2025-08-25 00:00 |
Quarterly Report
[기재정정]분기보고서 (2025.03)
|
Korean | 1.2 MB | ||
| 2025-08-25 00:00 |
Interim Report
[기재정정]반기보고서 (2025.06)
|
Korean | 1.2 MB | ||
| 2025-08-19 00:00 |
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
|
Korean | 118.2 KB | ||
| 2025-08-18 00:00 |
Legal Proceedings Report
투자판단관련주요경영사항(임상시험계획자진취하등) (췌장암 치료제 Polytaxel의 1상 임상시험계획 자진취하)
|
Korean | 11.1 KB | ||
| 2025-08-14 00:00 |
Interim Report
반기보고서 (2025.06)
|
Korean | 1.2 MB | ||
| 2025-08-08 00:00 |
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 24.4 KB | ||
| 2025-08-01 00:00 |
Post-Annual General Meeting Information
임시주주총회결과
|
Korean | 7.5 KB | ||
| 2025-07-23 00:00 |
Share Issue/Capital Change
권리락 (무상증자)
|
Korean | 3.5 KB | ||
| 2025-07-18 00:00 |
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
|
Korean | 116.0 KB | ||
| 2025-07-18 00:00 |
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 24.6 KB |
Automate Your Workflow. Get a real-time feed of all HYUNDAI BIOSCIENCE CO., LTD. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for HYUNDAI BIOSCIENCE CO., LTD.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for HYUNDAI BIOSCIENCE CO., LTD. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
